Research Paper Volume 12, Issue 24 pp 26063—26079

An Immuno-Clinic score model for evaluating T cell immunity and predicting early antiviral therapy effectiveness in chronic hepatitis B

Figure 4. Application of the ICS model in predicting antiviral therapy efficacy. (A) Evaluation of Immuno-Clinic scores at different time points during antiviral therapy within NAs, PEG-IFN, or total CHB patients. Data are presented as mean ± SEM. (B) The percentage of ICS-high or ICS-low patients at different time points during antiviral therapy are shown. Numbers in the blue and red proportion indicated the percentage of ICS-low and ICS-high patients, respectively. (C) Comparison of the ICS values between patients with different antiviral efficacy. In the upper panel, ΔICS at weeks 4 or 8 relative to week 0 were calculated. Data are presented as mean ± SEM. ***P < 0.001; *P < 0.05; NS=not significant. In the lower panel, pairs of the original Immuno-Clinic scores for each individual at weeks 4 or 8 and week 0 are shown.